Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ASPE with free AI briefings, catalyst countdowns, and dilution alerts.

ASPE · Aspen Neuroscience, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$72.4M Cash on Hand

15.3mo Cash Runway

Follow ASPE by email Get an email when ASPE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ASPE, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Nov 2, 2026 · Financing Completed IPO of 9,375,000 common shares at $15.00 per share, with gross proceeds of approximately $140.6 million before underwriting discounts and offering expenses. Amended and restated certificate of incorporation and bylaws became effective at closing.
Form 8-K · SEC filing
Oct 30, 2026 · Financing Priced IPO of 9,375,000 shares at $15.00 per share on Nasdaq under ASPE, with gross proceeds of $140,625,000 before underwriting discounts and expenses. Underwriters have a 30-day option to buy up to 1,406,250 additional shares.
Form 424B4 · SEC filing

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

Mar 2027 · Phase 1 · Enrolling · Phase 1/2a Study of ANPD001 in Parkinson Disease
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Danaparoid Sodium FDA approved Dec 1996 · Orgaran (discontinued)	Heparin-induced Thrombocytopenia	Phase 3 · NCT03809481	Terminated
Tinzaparin	Deep Venous Thrombosis	Phase 4 · NCT01828697	Completed
Dalteparin	Deep Venous Thrombosis	Phase 4 · NCT01828697	Completed
Enoxaparin	Deep Venous Thrombosis	Phase 4 · NCT01828697	Completed
Nadroparin	Deep Venous Thrombosis	Phase 4 · NCT01828697	Completed
Estriol	Vaginal Atrophy	Phase 2 · NCT04159493	Withdrawn
ANPD001	Parkinson Disease	Phase 1 · NCT06344026	Enrolling by invitation

Also used in these trials (approved or third-party drugs, not ASPE's own candidates): Sodium Chloride, Argatroban, Soybean Oil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ASPE holds $72.4M in cash and short-term investments and burns about $14.2M/quarter from operations, an estimated runway of 15.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 26 · Moderate

Cash runway 15 months +18
S-1 registration (Oct 2026) +8

Recent financing filings on SEC EDGAR:

Oct 30, 2026 · Underwritten offering, $141M · 424B4
Oct 9, 2026 · S-1 registration · S-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASPE files for a raise →

Get the full ASPE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASPE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z